Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 2, 2019--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30 a.m. Pacific Time at the Westin St. Francis in San Francisco.
A live webcast of the presentation will be available on the company’s website at www.akebia.com. To access, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akebia’s website following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005140/en/
CONTACT: Akebia Therapeutics Contact:
Melissa Forst / Maghan Meyers
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Akebia Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 01/02/2019 07:00 AM/DISC: 01/02/2019 07:01 AM